Table 1.

 Efficacy, event reduction, and approval status of lipid-lowering therapies

Class of agent	LDL reduction efficacy (%)	Event reduction	Approval status
Statins	30–50	+	+
Ezetimibe	15–20	+ Combined with statin	+
PCSK9 inhibitors	50–60	+ For MoAb combined with statin	+
Bempedoic acid	17–25	Outcome trial in progress	+

This table summarizes the efficacy and approval status for different therapies that target LDL.

LDL, low-density lipoprotein.